Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Talis Biomedical Corporation (“Talis”) (NASDAQ: TLIS) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Talis’ February 11, 2021 initial public offering (“IPO” or the “Offering”) between February 11, 2021 and August 11, 2021, inclusive (the “Class Period”).
The complaint alleges that the Registration Statement failed to disclose to investors that: (1) the comparator assay in the primary study lacked sufficient sensitivity to support Talis’ EUA application for Talis One COVID-19 test; (2) as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) as a result, Talis’ commercialization timeline would be significantly delayed; and (4) as a result of the foregoing, Defendants’ positive statements about Talis’ business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Current Status of Case:
On March 21, 2025, the Court granted Final Approval of the Class Action Settlement. This action has concluded.
Please be advised that the deadline to file a claim was March 13, 2025. You may find additional information regarding the terms of the settlement and claim filing process at www.talissecuritieslitigation.com, or by calling the claims administrator, A.B. Data, Ltd. at 1-877-331-0411.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.